TY  - JOUR
AU  - Dittrich, Tobias
AU  - Bochtler, Tilmann
AU  - Kimmich, Christoph
AU  - Becker, Natalia
AU  - Jauch, Anna
AU  - Goldschmidt, Hartmut
AU  - Ho, Anthony D
AU  - Hegenbart, Ute
AU  - Schönland, Stefan O
TI  - AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.
JO  - Blood
VL  - 130
IS  - 5
SN  - 1528-0020
CY  - Stanford, Calif.
PB  - HighWire Press
M1  - DKFZ-2017-04041
SP  - 632 - 642
PY  - 2017
AB  - The difference between involved minus uninvolved serum free light chains (dFLC) has been established as an invaluable hematologic parameter in systemic amyloid light chain (AL) amyloidosis. However, patients with an initial dFLC level <50 mg/L are currently deemed not evaluable for response to therapy. Therefore, we aimed to characterize this subgroup of patients and to define novel hematologic response parameters. We retrospectively analyzed 783 AL patients newly diagnosed at our center between 2002 and 2016. Patients with a dFLC level <50 mg/L showed smaller bone marrow plasmacytosis compared to patients with a dFLC level ≥50 mg/L (7
KW  - Immunoglobulin Light Chains (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:28550043
DO  - DOI:10.1182/blood-2017-02-767475
UR  - https://inrepo02.dkfz.de/record/128019
ER  -